story of the week
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet 2023 Nov 11;402(10414)1773-1785, AC Ford, A Wright-Hughes, SL Alderson, PL Ow, MJ Ridd, R Foy, G Bianco, FL Bishop, M Chaddock, H Cook, D Cooper, C Fernandez, EA Guthrie, S Hartley, A Herbert, D Howdon, DP Muir, T Nath, S Newman, T Smith, CA Taylor, EJ Teasdale, R Thornton, AJ Farrin, HA EverittFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.